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CTGF has been cloned from human umbilical vein endothelial
cells and identified as a major chemotactic and mitogenic factor
for connective tissue cells (Bradham et al, 1991). The protein
shares a 28–38% overall amino acid identity to the classical
IGFBPs and contains critical conserved sequences, including the
common IGFBP motif GCGCCxxC in the N-terminal part. After
demonstration of IGF binding to CTGF, it was termed IGFBP-8
(Kim et al, 1997), but, because the IGF binding affinity was very
low, IGFBP-8 was renamed insulin-like binding protein-related
protein 2 (IGFBP-rP2) (Baxter et al, 1998). Insulin-like growth
factors and their binding proteins have been shown to be an
integral part of the growth modulation of a number of neoplasms,
either by direct interaction with the IGF signalling pathway or in
an IGF-independent manner (Oh et al, 1995; Westley and May,
1995; Baserga et al, 1999). CTGF (IGFBP-rP2) is the second of
ten identified members of a low-affinity binding subgroup in the
IGFBP superfamily, and appears to regulate cell growth through a
largely IGF-independent mechanism (Hwa et al, 1999a).
Nomenclature of this group of molecules has become controver-
sial as investigators from a wide variety of backgrounds have
found evidence of the CTGF (IGFBP-rP2) compounds in the
course of their studies. The presence of many well-conserved
functional domains belonging among others to the CCN and to the
IGFBP superfamily and the wide spectrum of biological activities
led to multiple name changes that are confusing. Despite the fact
that we approached our studies from the IGF field, we are going to
use the acronym CTGF (IGFBP-rP2), which at this time may be
most appropriate. The CTGF (IGFBP-rP2) gene encodes a 38-kDa
prepeptide containing 349 amino acids. Northern blot analysis of
various normal human tissues showed expression of CTGF
(IGFBP-rP2) mRNA at high levels in spleen, ovary, gastroin-
testinal tract, prostate, heart and testis and up-regulation of CTGF
(IGFBP-rP2) after TGF-β stimulation of human breast cancer cells
(Yang et al, 1998; Hishikawa et al, 1999). No expression was
found in peripheral blood leukocytes, liver and brain (Kim et al,
1997). CTGF (IGFBP-rP2) was found to be highly expressed in
fibrotic skin diseases and negatively correlated with the malignant
potency of mesenchymal tumours, as well as their ability to
express CD34 antigen (Igarashi et al, 1998). Furthermore, positive
expression of CTGF (IGFBP-rP2) was found in the fibrous stroma
of mammary tumours and in neuroblastomas and gliomas,
although not in all specimens investigated (Frazier and
Grotendorst, 1997). Since a number of groups have reported
changes in serum or cerebrospinal fluid levels of IGFBPs in
patients with ALL, IGFBPs and their related proteins have became
subjects of intensive research in human neoplasia (Muller et al,
1994; Mohnike et al, 1996; Kim et al, 1997; Wex et al, 1998; How
et al, 1999).
In the present study, we have investigated the expression of
CTGF (IGFBP-rP2) in leukaemic cells of patients with ALL, or in
established leukaemia cell lines, by RT-PCR. Leukaemic cells
from patients with CML, peripheral MNC from patients with
IDDM, CD34+ stem cells from cord blood of healthy newborns
and peripheral CD34+ stem cells from patients with sarcomas were
used as controls.
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Summary Connective tissue growth factor (CTGF) is a major chemotactic and mitogenic factor for connective tissue cells. The amino acid
sequence shares an overall 28–38% identity to IGFBPs and contains critical conserved sequences in the amino terminus. It has been
demonstrated that human CTGF specifically binds IGFs with low affinity and is considered to be a member of the IGFBP superfamily (IGFBP-
rP2). In the present study, the expression of CTGF (IGFBP-rP2) in human leukaemic lymphoblasts from children with acute lymphoblastic
leukaemia (ALL) was investigated. RNA samples from tumour clones enriched by ficoll separation of bone marrow or peripheral blood
mononuclear cells (MNC) from 107 patients with childhood ALL at diagnosis and 57 adult patients with chronic myeloid leukaemia (CML)
were studied by RT-PCR. In addition MNC samples from children with IDDM and cord blood samples from healthy newborns were
investigated as control groups. Sixty-one percent of the patients with ALL (65 of 107) were positive for CTGF (IGFBP-rP2) expression. In the
control groups, no expression of CTGF (IGFBP-rP2) in peripheral MNC was detected, and in the group of adult CML patients only 3.5% (2 of
57) were positive for this gene. The role of CTGF (IGFBP-rP2) in lymphoblastic leukaemogenesis requires further evaluation, as does its
potential utility as a tumour marker. © 2000 Cancer Research Campaign
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Patient samples
Blood or bone marrow samples from 107 patients (age 1.2–21.9
years, median 6.0 years) with childhood acute lymphoblastic
leukaemia (ALL) at time of diagnosis (B-precursor ALL, n = 15;
B-ALL, n = 2; T-ALL, n = 22; c-ALL, n = 67; pre-T-ALL, n = 1)
from different ALL-BFM study centres were obtained. None of the
ALL-patients received any drugs before the first blood or bone
marrow sample was drawn. From 43 of these patients (B-precursor
ALL, n = 6; B-ALL, n = 2; T-ALL, n = 8; c-ALL, n = 27), addi-
tional samples were obtained at day 33 after the initiation of
chemotherapy, according to the ALL-BFM 90/95 protocol of the
German Society of Pediatric Oncology and Hematology.
All 43 patients were in full haematological remission at day 33.
Additionally, blood or bone marrow samples from 57 patients (age
6.4–84 years, median 47.8 years) with chronic myeloid leukemia
(CML), 120 blood samples from 47 children (age 1.8–15.8 years,
median 10.9) with insulin-dependent diabetes mellitus (IDDM),
100 cord blood samples from healthy newborns, and two samples
of peripheral stem cells from patients with sarcomas, before high-
dose chemotherapy for stem-cell rescue, were investigated (Tables
1 and 2). Informed consent was obtained from the participating
patients or their parents in adherence with the guidelines of the
Ethics Committee. The cytometric immunophenotyping of
haematopoietic malignancies was carried out in local and refer-
ence laboratories according to a consensus protocol (Rothe and
Schmitz, 1996).
Cell lines and cultures
Cell lines were obtained from the German Collection of
Microorganisms and Cell Cultures (Braunschweig, Germany) or
ATCC (Rockville, MD, USA) and grown according to the recom-
mended conditions. Molt-4, Karpas 299, Jurkat and HSB-2 are of
T-cell origin, whereas Karpas 422, cell line 380 and cell line 697
are of B-cell origin (Table 3). The origins of Raji, JVM-3, JVM-13
and U 937 are specified in Table 3.
Separation of mononuclear cells (MNC)
MNC were separated using gradient centrifugation with Ficoll-
Paque (Pharmacia, Uppsala, Sweden). At the time of diagnosis, the
tumour clones generally represented 50–90% of MNC fraction.
Separation of CD34+/CD38+ stem cells
CD34+/CD38+ progenitor cells were stained from peripheral blood
and separated by standard methods, using a FACSort machine
(Becton Dickinson, Heidelberg, Germany). Approximately
100 000 cells were separated and used for extraction of RNA.
RNA isolation/cDNA synthesis
Total RNA was extracted using QIAshredder®, RNeasy®, and
RNase-free DNase set (Qiagen, Hilden, Germany), following the
manufacturer’s protocol. The RNA was stored at –80° C until use.
2 µ g of total RNA were reverse transcribed into cDNA by
Omniscript reverse transcriptase (Qiagen), as recommended by the
manufacturer.
Enzymatic amplification of the cDNA
0.5 µ l aliquots of cDNA were used for enzymatic amplification
in 50 µ l reactions containing 10 × reaction buffer mixture, 1 unit
Prime Zyme Taq-polymerase (Biometra, Göttingen, Germany) and
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Table 1 Expression of CTGF (IGFBP-rP2) in MNC of patients with ALL, CML, IDDM and sarcoma as well as cord blood of
healthy newborns. 60.7% of all ALL patients were positive for CTGF (IGFBP-rP2) expression in MNC. aThere is a statistically
significant difference in CTGF (IGFBP-rP2) expression in the malignant lymphoblasts between the immunological subtypes of
ALL. Only 1.5% of CTGF (IGFBP-rP2)-positive patients showed a T-immunophenotype, whereas 52% of negative patients
have been classified as T-ALL. bThe control groups differ significantly from the ALL group in regard to CTGF (IGFBP-rP2)
expression. Only CML patients expressed in 3.5% CTGF (IGFBP-rP2). IDDM patients and isolated CD34+ stem cells were
CTGF (IGFBP-rP2)-negative
Patients Material Cell n = CTGF Origin
type expression
Blood or bone positive* B-cell: 98.5% (n = 64)
ALLb marrow MNC 107 60.7% (n = 65) T-cell: 1.5% (n =1 )
negative* B-cell: 47.6% (n = 20)
39.3% (n = 42) T-cell: 52.4% (n = 22)
Blood or bone positive
CMLb marrow MNC 57 3.5% (n =2 )
negative
96.5% (n = 55)
IDDMb Blood MNC 120 negative
100% (n = 120)
CD
Sarcoma Blood 34+ 2 negative
100%(n =2 )
CD
Newbornsb Cord blood 34+ 100 negative
100% (n = 100)0.2 pmol of both gene-specific primers in a Hybaid Gene
Thermocycler (Hybaid). Initial denaturation at 95° C for 5 min was
followed by 35 cycles with denaturation at 95° C for 1 min,
annealing at 62° C for 1 min and elongation at 72° C for 0.5 min.
The final elongation step was extended to 15 min. One-fifth of the
reaction mix was loaded onto a 1.75% agarose gel, separated by
electrophoresis at 5 V cm–1 in TAE buffer and stained with
ethidium bromide. CTGF forward primer: CAACTGCCTG-
GTCCAGACC corresponding to nucleotide numbers 371–389;
CTGF reverse primer: CACTCTCTGGCTTCATGCC corre-
sponding to nucleotide numbers 842–824 of the human CTGF-
mRNA, GenBank accession number U14750. β -actin forward
primer: GCTGGGGTGTTGAAGGTCTC; β -actin reverse primer:
CTCCGGCATGTGCAAGGC.
The resulting PCR products are 471 bp (CTGF) and 351 bp
(β -actin) long (Figure 1).
Statistical analysis
For statistical analysis χ 2 test was performed with SPSS Version
9.1 at P = 0.001. Confidence intervals for 95% are estimated
according to the number of patients using confidence interval
tables.
RESULTS
MNC from 60.7% of the patients with ALL (65 of 107) were posi-
tive for CTGF (IGFBP-rP2) expression at diagnosis. All other
groups are statistically significantly different from the ALL group
(P < 0.001). In the group of CML patients, MNC from only 3.5%
(2 of 57) were positive for CTGF (IGFBP-rP2). No expression was
detected by RT-PCR in MNC from diabetics, cord blood samples
or peripheral stem cells (Table 1).
98.5% (n = 64) of the patients in the group of CTGF (IGFBP-
rP2) expression positive ALL patients (n = 65) showed an
immunological subtype of B-cell origin (c-ALL or B-ALL) and
only 1–5% (n = 1) was from T-cell origin. The CTGF (IGFBP-rP2)
negative ALL patients are statistically significant (P < 0.001)
different in their immunological background. 52.4% (n = 22) of 
CTGF (IGFBP-rP2) negative ALL patients were immunologically
classified as T-ALL and only 47.6% (n = 20) were immuno-
logically from B-cell origin (Table 1).
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Table 2 Expression of CTGF (IGFBP-rP2) in 43 patients with ALL at different time-points. Expression in lymphoblasts was
studied by RT-PCR at diagnosis and at day 33 according the ALL-BFM-therapy protocol. The values are expressed in percent of
the respective group with the 95% confidence interval
CTGF at diagnosis CTGF at day 33 In % of
(total n = 43) (total n = 43) total n
Negative 83.3% (62.6–95.3%) (n = 20) 46.5%
Positive 55.8% (n = 24)
Positive 16.7% (4.7–37.4%) (n = 14) 9.3%
Negative 73.7% (48.8–90.8%) (n = 14) 32.6%
Negative 44.2% (n = 19)
Positive 26.3% (9.2–51.2%) (n = 5) 11.6%
Table 3 Expression of CTGF (IGFBP-rP2) mRNA by RT-PCR in different lymphatic cell lines. Only cell lines established
from patients with childhood ALL of B-origin (380, 697) were found to be positive for CTGF (IGFBP-rP2) expression
CTGF
Cell line Origin (IGFBP-rP2)
Raji Established from the left maxilla of an 11-year-old African boy Negative
with Burkitt’s lymphoma
JVM-3 Human chronic B cell leukaemia, established from the peripheral Negative
blood of a 73-year-old man with B-prolymphocytic leukaemia
JVM-13 Human chronic B cell leukaemia, established from the peripheral Negative
blood of a patient with B-prolymphocytic leukaemia
Karpas 422 Pleural effusion of a 73-year-old woman with B cell Non-Hodgkin’s Negative
lymphoma
U 937 Pleural effusion of a 37-year-old man with histiocytic Negative
lymphoma cells express markers and properties of monocytes
Molt-4 Peripheral blood of a 19-year-old man with T-ALL in relapse Negative
Karpas 299 Peripheral blood of a 25-year-old man with T cell non-Hodgkin’s Negative
lymphoma
Jurkat Peripheral blood of a 14-year-old boy with T-ALL Negative
HSB-2 Peripheral blood of an 11.5-year-old boy with T-ALL Negative
380 Peripheral blood of a 15-year-old boy with B-ALL in relapse Positive
697 Bone marrow of a 12-year-old boy with c-ALL at relapse PositiveCTGF expression in ALL 759
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We were able to investigate a second MNC sample from day 33
of chemotherapy in 43 ALL patients. On this day, all 43 patients
had achieved haematological remission. Twenty-four (55.8%) of
these 43 ALL patients expressed CTGF (IGFBP-rP2) mRNA at
diagnosis. Twenty patients (83.3%) of these 24 initially CTGF
(IGFBP-rP2)-positive patients became negative for CTGF
(IGFBP-rP2) after the initial treatment, whereas four patients
remained positive (16.7%). From the 19 of 43 (44.2%) initially
CTGF (IGFBP-rP2)-negative ALL patients, 14 remained negative
and five became positive for CTGF (IGFBP-rP2) mRNA expres-
sion (Table 2).
From the 11 cell lines studied for CTGF (IGFBP-rP2) expres-
sion only those established from patients with childhood ALL of
B-cell origin (380 and 697) were found to express CTGF (IGFBP-
rP2) mRNA by RT-PCR (Table 3).
DISCUSSION
Insulin-like growth factor binding proteins (IGFBPs) are a group
of homologous proteins that regulate the biological activities of
IGFs and may also act in an IGF-independent manner (Oh et al,
1993; Rosenfeld et al, 1994; Jones and Clemmons, 1995). In addi-
tion to the six well-characterized IGFBPs with high affinity for
IGF, at least ten additional proteins have been reported to have a
significant structural relationship (Hwa et al, 1999a; 1999b).
These proteins contain conserved cysteines in the NH2-terminal
region, including the ‘IGFBP-motif’ (GCGCCXXC). To date,
specific IGF binding has been described in at least three new
members of the IGFBP superfamily, MAC25 (IGFBP-rP1), CTGF
(IGFBP-rP2), and Nov-H (IGFBP-rP3) (Oh et al, 1996; Kim et al,
1997; Burren et al, 1999).
Proceeding from our previous reports on expression of insulin-
like growth factors and their binding proteins in human leukaemic
lymphoblasts, we studied the gene expression of new members
of the IGFBP superfamily in leukaemia (Wex et al, 1998).
Preliminary RT-PCR data suggested, that in contrast to Mac25
(IGFBP-rP1), Nov-H (IGFBP-rP3) and Cyr61 (IGFBP-rP4), only
CTGF (IGFBP-rP2) is specifically expressed in leukaemic
lymphoblasts (data not shown).
In the present study we demonstrate by RT-PCR that CTGF
(IGFBP-rP2) mRNA is specifically expressed in more than 60% of
patients with acute lymphoblastic leukaemia at the time of diag-
nosis. In contrast to this finding, no expression of CTGF (IGFBP-
rP2) mRNA could be detected in peripheral blood lymphocytes of
control persons with IDDM, myeloid leukaemic cells of CML-
patients or stem cells from peripheral blood or cord blood.
Our data demonstrate for the first time that especially leukaemic
B-, but also T-cells of patients with ALL are able to express CTGF
(IGFBP-rP2). The disappearance of gene expression after
chemotherapy in the majority of initial CTGF (IGFBP-rP2)-posi-
tive patients may reflect the disappearance of the leukaemia cells
themselves. However, although all patients reached apparently
complete haematological remission at day 33, 16.7% of all initial
CTGF (IGFBP-rP2)-positive patients remained positive, and a
number of initially negative patients expressed the gene at this
time-point.
To investigate whether the ability of the leukaemic cell
population to express CTGF (IGFBP-rP2) is a property of all
lymphoid progenitors, and not exclusive for leukaemia cells, we
investigated CD34+/CD38+ cell populations for expression of
CTGF (IGFBP-rP2). Our data demonstrate that normal lymphoid
progenitor cells from cord blood do not express CTGF (IGFBP-
rP2). Furthermore, CD34+/CD38+ progenitor cells for stem cell
rescue from two patients with sarcomas prior to high-dose
chemotherapy were negative for CTGF (IGFBP-rP2) expression.
Therefore, we conclude, that CTGF (IGFBP-rP2) expression in
leukaemic lymphoblasts of patients with childhood ALL is specific.
The fact that only cell lines with B-origin from patients with
childhood ALL expressed CTGF (IGFBP-rP2) reflects the situa-
tion in our ALL patients. The majority of patients with T-ALL do
not express CTGF (IGFBP-rP2) in their malignant lymphoblasts.
At this time, there are insufficient data concerning the outcome
of ALL in patient groups with different CTGF (IGFBP-rP2)
expression patterns. Further investigations of CTGF (IGFBP-rP2)
in ALL and other neoplasms are necessary to investigate the role
of this protein in the pathogenesis of these diseases, and its poten-
tial role as a tumour marker or MRD parameter.
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